The rise of Covid 19 is taking new heights every day. With the introduction of the new Covid 19 variant, Omicron the danger level might have increased in the world. The demand for effective vaccination has started again and The Federal government has urged all the unvaccinated citizens to get the vaccination done soon in order to protect from this new variant.
The Trail Phaze Of Merck Shows Positive Results
At the starting of October month, Merck & Co. applied for the emergency use of molnupiravir which is an antiviral tablet to reduce hospitalization and death risk.
According to Merck and Ridgeback’s Analysis of Phase 3 Study, Molnupiravir, an investigational oral antiviral, reduced the risk of hospitalization or death by approximately 50% for patients with mild or moderate COVID-19. On the other hand, Pfizer Paxlovid antiviral pills have shown promising results and applied for emergency use.
But many health experts have stated that antiviral pills must not be considered as an alternative for booster shots.
As per the latest analysis done by the Central Government Medical Agencies it has been found that the antiviral pill “Molnupiravir” has shown better results and is very effective to fight against the virus in the long run. But they are still not confirmed about the approval and stated that the agency might consider consulting some outside medical experts to check the risk of the antiviral pills during the pregnancy.
ness. The FDA scientists said their review identified several potential risks which require some external support and consultation.
The Food and Drug Administration advisory panel has decided to meet on 30 November to discuss every minute detail about the Molnupiravir antiviral pills from Merck. The meeting will be held to analyze the supporting data that can allow the use of Merck Antiviral pill molnupiravir for the treatment of mild symptom Covid 19 patients and also for those who are at high risk of hospitalization and death.
Currently, the Federal Government has allowed the use of booster shots to increase the immunity system which will help to fight the virus. The new variant possesses more risk of hospitalization and the level spread can be very high. So the FDA needs to discuss and check all the ifs and buts related to the antiviral pills and authorize the emergency use of the pills for the treatment.
Pfizer has set out to obtain its own Covid-19 antiviral tablet, Paxlovid, on the market after Merck’s antiviral molnupiravir received UK clearance. The US pharmaceutical applied to the US Food and Drug Administration (FDA) for an emergency use authorization for its new antiviral pills with mild-to-moderate Covid-19 who are at danger of hospitalization or death.
Pfizer has also started the process of getting approval in other countries, including the United Kingdom, New Zealand, and South Korea, and plans to target other countries as well.
Since trials revealed it lowered hospitalization and death risk by roughly 50%, Merck’s molnupiravir, the first licensed tablet for Covid-19, has been hailed as a possible game-changer. But it doesn’t keep Pfizer out of the competition as their pills have also shown 80 percent effectiveness.
